🔗 Share this article

Given that the US continues making sweeping adjustments to its vaccine recommendations, an unexpected name has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by questioning Covid shots during the pandemic and has concentrated on alleged deaths following COVID-19 vaccination in her recent time at the FDA.

Scheduled Changes to Pediatric Vaccine Program

Agency leaders had intended to announce sweeping revisions to the childhood immunization program in December, bringing the US with Denmark’s vaccine program, it is understood – a major change that would put the US out of alignment with much of the international standard with little proof for improved outcomes. The planned update has been pushed back until the coming year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to present at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Prasad consolidate power at the agency – and it points to a renewed priority upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric immunization guidelines in the US so as to align more like Denmark, a society with universal health coverage and a citizenry about the population of the state of Wisconsin.

To date public appearances, she has continued to focus on vaccination policy – usually the responsibility of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Expertise

Dr. Høeg has no apparent experience in medication creation, approval processes or management, which has been typical for past heads of the biologics center. She has served at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have the necessary background” for leading the CDER, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in running a major agency. She has no expertise in drug approvals.”

Past directors of CBER would “grasp regulatory frameworks and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Clearly, she lacks the type of experience that former directors who ran the center have had.”

This division has an enormous range of responsibilities at the agency, she emphasized.

“Many people just pays attention on the innovative therapies, but the off-patent medication office authorizes a multitude of generic medications. There’s a biosimilars program, OTC medication office and more, and each of these must be looked after,” Dr. Woodcock said. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

There is also, a major leadership aspect to the position, which manages in excess of 5,000 employees. “It’s a huge administrative position, if you do it right,” Woodcock concluded.

Response and Contentious Programs

In response to inquiries about Dr. Høeg's qualifications and whether this assignment indicates greater collaboration among agency officials on vaccines, a press secretary responded that the “inquiries rely on incorrect assumptions”.

“Her resume matches the responsibilities of her job,” the representative said, citing the period Dr. Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg inherits the commissioner’s new expedited review system, a disputed rapid drug-approval program that reportedly troubled her predecessors. “By what process are these drugs being chosen for this expedited pathway? Who takes the calls?” Dr. Howard asked. “There’s a lot of secrecy going on at the FDA right now.”

Overall, he stated, “the FDA appears to be shifting towards more relaxed regulations of most medications, except for vaccines.”

Established Past Work on Vaccines

With vaccines, Dr. Høeg has a more established, if concerning, past, Howard have noted. She released a research paper using unconfirmed public submissions to determine the frequency of myocarditis after Covid vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are riskier than they are.

Part of her “policy goals” for the current administration included altering rules for new vaccines and ending “optional” immunizations, she said following the vote on a online show. At the agency, Dr. Høeg has allegedly suggested excluding adolescent males from obtaining Covid vaccines.

“She’s an thorough dogmatist who commences with her beliefs and tailors the evidence to fit the data in a extremely deceptive, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg aligned with fellow dissenters, {like|